A pivotal Phase III trial of of CLR 131 in multiple myeloma and other hematologic malignancies.
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2016
At a glance
- Drugs CLR 1404 I-131 (Primary)
- Indications Haematological malignancies; Multiple myeloma
- Focus Therapeutic Use
- 27 Nov 2016 New trial record
- 15 Nov 2016 According to a Cellectar Biosciences media release, company plans to use the results of Phase II trial (see profile 275778) in designing of this trial.